Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Genomics in myelofibrosis: practical guidelines for its use in clinical practice

Raajit Rampal • 25 Aug 2020
SOHO 2020
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

Raajit Rampal, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses practical guidelines for the use of genomics in the treatment and management of myelofibrosis. Specifically discussed is the growing understanding of the landscape of prognostic mutations and the implications of this on treatment approaches including transplantation, and the use of targeted agents such as ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Raajit Rampal

Fibrotic progression of ET and PV: clinical and biological considerations
Raajit Rampal • 24 Nov 2022
1:00
How genomic testing has influenced treatment approaches and clinical trial design in MPNs
Raajit Rampal • 26 Aug 2022
1:05
Venetoclax-based combinations in patients with accelerated and blast-phase MPNs
Raajit Rampal • 26 Aug 2022
0:46
The prognostic impact of TP53 mutation in MPNs
Raajit Rampal • 26 Aug 2022

Related Videos

1:35
Addressing the increased risk of cardiovascular disease in patients with MPNs
Arjun Ghosh • 25 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals